Prenatal Zidovudine Use and Congenital Anomalies in a Medicaid Population
- 1 July 2000
- journal article
- research article
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 24 (3) , 249-256
- https://doi.org/10.1097/00126334-200007010-00009
Abstract
To explain the low transmissibility and pathogenicity of HIV-2 infection’s plasma viral loads in both HIV-1- and HIV-2-infected persons were compared by using the polymerase chain reaction (PCR)-based Amp-RT assay to measure levels of reverse transcriptase (RT) activity. The study comprised a total of 155 HIV-infectedpeople including 58 who were infected with HIV-2 with CD4+ cell counts 500 × 106/L (n = 26), or with tuberculosis (TB; n = 17), and 97 HIV-1-infected people with CD4+ cell counts 500 × 106/L (n = 25), or TB (n = 40). Among persons with CD4+ cell counts 500 × 106/L, none of 26 HIV-2-infected persons had detectable RT activity compared with 13 (52%) of 25 HIV-1-infected persons (p < .001). Our data suggest that unlike HIV-1 infection, HIV-2 infections with CD4+ cell counts >500 × 106/L are associated with a low level of viral replication, which may explain the longer clinical latency and lower transmissibility seen in HIV-2 infection. Address correspondence and reprint requests to Walid Heneine, HIV and Retrovirology Branch, Centers for Disease Control and Prevention, 1600 Clifton Road, MS-G19, Atlanta, GA 30333, U.S.A.; email: [email protected] Use of trade names is for identification only and does not imply endorsement by the Public Health Service or the U.S. Department of Health and Human Services. This work was presented in part at the 5th National Conference on Retroviruses and Opportunistic Infections, Chicago, Illinois, U.S.A., 1998 [abstract 578]. Manuscript received December 7, 1999; accepted April 3, 2000. © 2000 Lippincott Williams & Wilkins, Inc.Keywords
This publication has 16 references indexed in Scilit:
- Translating Clinical Trial Results into Practice: The Effect of an AIDS Clinical Trial on Prescribed Antiretroviral Therapy for HIV-Infected Pregnant WomenAnnals of Internal Medicine, 1999
- Incorporation of zidovudine into leukocyte DNA from HIV-1-positive adults and pregnant women, and cord blood from infants exposed in uteroAIDS, 1999
- Safety of the maternal–infant zidovudine regimen utilized in the Pediatric AIDS Clinical Trial Group 076 StudyAIDS, 1998
- Fetal, Infant, and Maternal Toxicity of Zidovudine (Azidothymidine) Administered Throughout Pregnancy in Macaca nemestrinaJAIDS Journal of Acquired Immune Deficiency Syndromes, 1998
- Transplacental Effects of 3'-Azido-2',3'-Dideoxythymidine (AZT): Tumorigenicity in Mice and Genotoxicity in Mice and MonkeysJNCI Journal of the National Cancer Institute, 1997
- Reduction of Maternal-Infant Transmission of Human Immunodeficiency Virus Type 1 with Zidovudine TreatmentNew England Journal of Medicine, 1994
- The transfer of anti-human immunodeficiency virus nucleoside compounds by the term human placentaAmerican Journal of Obstetrics and Gynecology, 1992
- Zidovudine-Associated Embryonic Toxicity in MiceThe Journal of Infectious Diseases, 1991
- Postnatal survival in Wistar rats following oral dosage with zidovudine on Gestation Day 10Fundamental and Applied Toxicology, 1990
- Computing an Exact Confidence Interval for the Common Odds Ratio in Several 2 × 2 Contingency TablesJournal of the American Statistical Association, 1985